Sandoz has delivered first-half results that reflect the strength of its business in Europe and the continuing expansion of its biosimilars segment, with double-digit growth for both aspects of the business helping to push up its sales in both the second quarter and first half of 2023.
Second-quarter sales came in at $2.379bn – up 5% as reported and 8% at constant currencies – with volume contributing...






